Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Carmen Bozic Biography and Net Worth

CMO of Vertex Pharmaceuticals

Carmen has deep experience leading global clinical development programs across all phases of development and across multiple diseases and therapeutic modalities. She joined Vertex in 2019 and is responsible for developing and driving the execution of our clinical development programs, including clinical development, medical affairs, drug safety, global clinical operations and biometrics.

She graduated with her medical degree from McGill University, where she also completed a residency in internal medicine and served as Chief Resident. She completed a combined fellowship in pulmonary and critical care medicine at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center.

Carmen serves as a member of the Clinical Advisory Committee at Akili Interactive. Previously she was the industry representative to the U.S. Food and Drug Administration’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee.

What is Carmen Bozic's net worth?: The estimated net worth of Carmen Bozic is at least $10.39 million as of August 7th, 2024. Dr. Bozic owns 23,259 shares of Vertex Pharmaceuticals stock worth more than $10,387,935 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Bozic may own. Learn More about Carmen Bozic's net worth.
How do I contact Carmen Bozic?: The corporate mailing address for Dr. Bozic and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Carmen Bozic's contact information.
Has Carmen Bozic been buying or selling shares of Vertex Pharmaceuticals?: Carmen Bozic has not been actively trading shares of Vertex Pharmaceuticals over the course of the past ninety days. Most recently, Carmen Bozic sold 2,280 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a transaction totalling $1,086,990.00. Following the completion of the sale, the chief marketing officer now directly owns 23,259 shares of the company's stock, valued at $11,088,728.25. Learn More on Carmen Bozic's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Carmen Bozic Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2024	Sell	2,280	$476.75	$1,086,990.00	23,259
7/24/2024	Sell	2,280	$488.46	$1,113,688.80	25,539
7/10/2024	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Sell	2,280	$478.00	$1,089,840.00	32,379
5/29/2024	Sell	2,280	$445.56	$1,015,876.80	34,659
10/31/2023	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Sell	5,651	$373.25	$2,109,235.75	40,603
10/3/2023	Sell	5,651	$345.28	$1,951,177.28	46,254
9/19/2023	Sell	5,651	$351.00	$1,983,501.00	51,905

Carmen Bozic Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $449.32

$445.00

$455.43

50 Day Range

MA: $475.38

$448.01

$516.74

2 Week Range

Now: $449.32

$346.29

$519.88

Volume

1,080,102 shs

Average Volume

1,187,284 shs

Market Capitalization

$115.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Trump won. Buy this coin now.

From Weiss Ratings | Ad